Primary malignant melanoma of the esophagus

Chunxiang Ling1, Jizhen Feng1, Jiamei Li2, Qingwei Liu1

1Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
2Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China

Dear Editor,

Primary malignant melanoma of the esophagus (PMME) is a rare disease that accounts for 0.1%-0.2% of the total primary malignant tumors of the esophagus (1).

A 62-year-old Chinese male presented with a 1-month history of dysphagia for solids accompanied by odynophagia. There was no past history of cutaneous, ocular, or other site melanomas. An esophagogastroduodenoscopy (EGD) performed in our outpatient department revealed a polypoid tumor in the lower esophagus, at a site 33 cm from the incisors, accompanied by hyperemia and erosion (Figure 1). An endoscopic biopsy of the lesion was performed. The samples were sent for a pathological examination, which revealed melanoma (Figure 2). A double-contrast esophagogram showed an irregular filling defect localized in the lower esophagus, expanding the distal esophagus without causing obstruction. A contrast-enhanced (CE) computed tomography (CT) scan of the thorax and the abdomen revealed the presence of eccentric thickening of the lower esophagus wall, with a moderate enhancement (Figure 3). There were no apparent metastases. Therefore, an esophagectomy with extensive lymph node dissection was performed, and the specimen was sent for pathological examination. The diagnosis was PMME. The patient had a consistent fever 1 day after surgery due to lung infection and hydrothorax, and he requested to be discharged home 25 days after the surgery without palliative chemotherapy, radiotherapy, and a routine CT follow-up because of the poor prognosis of the disease and financial constraints. The patient being in a poor postoperative condition still only eats liquid food and is followed up via telephone. A written informed consent was obtained from the patient for his participation in this study.

Primary malignant melanoma of the esophagus is a rare disease that accounts for 0.1%-0.2% of the total pri-
Primary malignant tumors of the esophagus. It most often occurs in men, and most patients are in their sixth and seventh decades (1). Dysphagia and epigastralgia are the chief complaints of patients with PMME (2). Nonspecific clinical symptoms are easily ignored, which delays the diagnosis. In approximately 90% of the PMME cases, the most frequent location is in the middle or the distal third of the esophagus probably because of a greater concentration of melanocytes in these regions (1,3).

A double-contrast esophagogram in PMME usually reveals a smooth-surface tumor that is lobulated, polypliod, protruding, or sectionalized and has a tendency of growing in the radial or horizontal directions. The tumor region is often distended, which makes it different from other esophageal malignant tumors (2).

A CE-CT examination demonstrates the esophageal lesion with regard to its size, shape, degree of local spread, lymph node invasion, and remote metastatic disease. Magnetic resonance can facilitate preoperative diagnosis because it detects high-signal-intensity masses in the esophagus on T1-weighted imaging because of the paramagnetic scavenging by melanin. A positron emission tomography and computed tomography (PET/CT) examination is also useful in the PMME treatment program particularly to evaluate the effect of postoperative therapy and search for occult metastasis (4–6). In our case, the patient declined PET/CT examination because of financial constraints.

Positive findings of S100 protein and HMB45 by immunohistochemical staining are sometimes necessary to diagnose PMME in certain cases, particularly when an ordinary histologic examination is insufficient (2,7).

The differential diagnosis of PMME includes squamous cell carcinoma, spindle cell carcinoma, leiomyosarcoma, lymphoma, rhabdomyosarcomas, epidermoid and small cell carcinoma, Kaposi’s sarcoma, and adenocarcinoma arising from a Barrett’s esophagus. It is hard to differentiate these tumors based on radiological signatures, but there are some manifestations that can point to some of them.

Primary malignant melanoma of the esophagus prognosis is fatal, with a median survival rate of 34.5 months after surgery, regardless of the treatment (8). The only therapeutic option that impacts survival is surgical treatment. The most important prognostic factor and predominant death cause is the presence of metastases (8,9). Therefore, because tumor cells longitudinally disseminate, a total or near-total esophagectomy is essential (10).

Primary malignant melanoma of the esophagus is a rare tumor with fatal prognosis. It is hard to distinguish it from non-epithelial malignant tumors because of the limited information supplied by radiological images. Therefore, the diagnosis of PMME should combine clinical symptoms, auxiliary examination, pathological examination, and immunohistochemistry.

**Informed Consent:** Informed consent was obtained from the patient who participated in this study.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Concept - C.L., Q.L.; Design - C.L., J.F.; Supervision - J.F., Q.L.; Resources J.L., Q.L.; Materials - C.L., J.L.; Data Collection and/or Processing - C.L., J.F.; Analysis and/or Interpretation C.L., J.F.; Literature Search - C.L., Q.L.; Writing Manuscript - C.L.; Critical Review - J.F., J.L., Q.L.

**Conflict of Interest:** The authors have no conflict of interest to declare.

**Financial Disclosure:** This study was supported by grants from Natural Science Foundation of China (#81502568).

**REFERENCES**

2. Iwanuma Y, Tomita N, Amato T, et al. Current status of primary malignant melanoma of the esophagus: clinical features, pathol-


